GALECTIN THERAPEUTICS GT
Live / Registered — Registered and renewed (as of 13 May 2024)
What this means for you
Registered since 04 Mar 2014. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 04 Mar 2024).
Record
- Serial number
- 85873661
- Registration number
- 4492469
- Mark type
- Design + words
- Filed
- 12 Mar 2013
- Published for opposition
- 10 Sept 2013
- Registered
- 04 Mar 2014
- Next maintenance due
- 04 Mar 2024
- Attorney of record
- Joseph Agostino
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, namely, compounds for use in the treatment of nonalcoholic steatohepatitis, fibrosis, inflammatory and autoimmune disorders, neoplastic conditions, cancer, liver fibrosis, kidney fibrosis, lung fibrosis and/or heart fibrosis
Owner
- Galectin Therapeutics Inc., Norcross, GA, US
- Galectin Therapeutics Inc., Norcross, GA, US
- Galectin Therapeutics Inc., Norcross, GA, US
Prosecution history
- 13 May 2024 — NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
- 13 May 2024 — REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
- 13 May 2024 — REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
- 13 May 2024 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 26 Jan 2024 — TEAS SECTION 8 & 9 RECEIVED
- 04 Mar 2023 — COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
- 05 Jun 2020 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
- 05 Jun 2020 — REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
- 05 Jun 2020 — TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
- 06 Apr 2020 — POST REGISTRATION ACTION MAILED - SEC. 8 & 15
- 01 Apr 2020 — TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
- 01 Oct 2019 — POST REGISTRATION ACTION MAILED - SEC. 8 & 15
- 20 Sept 2019 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 13 Aug 2019 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 13 Aug 2019 — TEAS SECTION 8 & 15 RECEIVED